Osteal Therapeutics Closes $30 Million Series B Financing

Osteal Therapeutics completed an oversubscribed $30 million Series B equity financing. Proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate VT-X7 for treatment of periprosthetic joint infection (PJI) and fund new research.

Following the successful completion of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us